title: Efficacy and safety of levetiracetam in clinical practice: results of the SKATE trial from Belgium and The Netherlands.
abstract: OBJECTIVE
  Aim of the study was to assess the efficacy and safety of levetiracetam as add-on treatment in patients with partial-onset epilepsy in clinical practice.
  
  
  METHODS
  In this observational, multi-centre study patients were treated with levetiracetam for 16 weeks. From a starting dose of 1000 mg/day, dose levels were adjusted at 2-weekly intervals in 1000-mg steps, to a maximum of 3000 mg/day, based on seizure control and tolerance. Analysis of efficacy was based on reduction in seizure frequency relative to baseline, 50% and 100% responder rates (for partial seizures and all seizure types combined) and percentage of patients using levetiracetam at the end of the study. Analysis of safety was based on occurrence of adverse events.
  
  
  RESULTS
  The present analysis concerns the results of patients recruited in Belgium and The Netherlands. Of the 251 patients included in the study, 86.9% completed 16 weeks of treatment. Reduction in frequency of partial-onset seizures was 62.2%, with 19.3% of the patients becoming seizure free and 56.6% having a reduction in seizure frequency of > or = 50%. These percentages were more or less the same when calculated for all seizure types combined. Tolerance of levetiracetam treatment was good, with most adverse events being only mild to moderate in severity, and only 10.0% of the adverse events leading to discontinuation from the study. Asthenia, somnolence, dizziness and headache were the most frequently reported adverse events.
  
  
  CONCLUSIONS
  Levetiracetam is effective and safe as add-on treatment for partial-onset seizures in clinical practice.
authors.affiliation: Epilepsy Centre Kempenhaeghe, Sterkselseweg 65, 5591 VE Heeze, The Netherlands. LambrechtsD@kempenhaeghe.nl
authors.forename: D A J E
authors.initials: DA
authors.lastname: Lambrechts
authors.forename: B
authors.initials: B
authors.lastname: Sadzot
authors.forename: W
authors.initials: W
authors.lastname: van Paesschen
authors.forename: J A
authors.initials: JA
authors.lastname: van Leusden
authors.forename: J
authors.initials: J
authors.lastname: Carpay
authors.forename: P
authors.initials: P
authors.lastname: Bourgeois
authors.forename: E
authors.initials: E
authors.lastname: Urbain
authors.forename: P A J M
authors.initials: PA
authors.lastname: Boon
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D001530:Belgium; D002648:Child; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam